Clinical trials: Male Osteoporosis
Vasomotor Symptoms, Urinary Incontinence
Nurse-led Primary Healthcare Intervention Model in Women's Health Management in Hong Kong
The goal of this randomized clinical trial is to learn if a nurse-led primary healthcare intervention can help improve health management in women adults aged 45 to 64, and to develop an evidence-based primary healthcare model for…
- Conditions
- Vasomotor Symptoms, Urinary Incontinence, Anxiety, Depression - Major Depressive Disorder
- Trial name
- JCDATAZONEWH (NCT06628388)
- Testing
- Nurse-Led Risk-Based 5As Primary Healthcare Model, Minimal Intervention
- Where
- 3 sites in Hong Kong
- Volunteers
- 1,728 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Hiv, HIV Infections
Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil
Randomized controlled parallel open-label study in persons living with HIV. The aim is to study weight changes in patients switching from a dolutegravir and tenofovir disoproxil containing regimen to either a dolutegravir or…
- Conditions
- Hiv, HIV Infections, HIV Lipodystrophy, Osteoporosis
- Trial name
- AVERTAS-2 (NCT04903847)
- Testing
- Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]
- Where
- 5 sites in Denmark
- Volunteers
- 126 people
- Sponsor
- Thomas Benfield
End-Stage Renal Disease, Osteoporosis
Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
Alendronate is a safe and effective drug for treating osteoporosis in post-menopausal women. However, its safety and efficacy in increasing bone mineral density in chronic peritoneal dialysis (PD) patients have not been…
- Trial name
- NCT00261625
- Testing
- alendronate
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
The purpose of this study is to compare the effect of an investigational drug used intravenously and placebo administered every three months for one year, on bone loss associated with initial androgen deprivation) in men with…
- Trial name
- NCT00063609
- Testing
- zoledronic acid
- Where
- 44 sites in United States
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months.
- Trial name
- NCT06332014
- Testing
- Prolia
- Where
- 16 sites in China
- Volunteers
- 102 people
- Sponsor
- Amgen
Male Osteoporosis
The Effect Of Oral Ibandronate In Male Osteoporosis
Male osteoporosis is a common and important clinical problem, associated with significant morbidity, mortality and societal expense. Approximately 10% of men =65 years of age are osteoporotic.
- Trial name
- STRONG (NCT00397839)
- Testing
- Ibandronate
- Where
- 41 sites in United States
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease Requiring Chronic Dialysis, Osteoporosis
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Aims: 1. To determine whether BMD and muscle mass were associated with fractures and other adverse events in dialysis patients. 2.
- Trial name
- NCT02616627
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Osteoporosis, Age-Related, Humeral Fractures
Teriparatide for Fracture Repair in Humans
This study will test the hypothesis that daily subcuaneous administration of 20µg of teriparatide (TPTD) as compared to daily subcuaneous placebo for twelve weeks accelerates proximal 2-segment humerus fracture healing and…
- Trial name
- TERAFRAP (NCT02091492)
- Testing
- Teriparatide
- Where
- Austria
- Sponsor
- Medical University of Vienna
Prostatic Neoplasms
Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer
The aim of this study is to comprehensively monitor the effects of a nonsteroidal antiandrogen in patients requiring hormone manipulation for prostate cancer
- Trial name
- NCT00551044
- Testing
- Bicalutamide
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Wirral University Teaching Hospital NHS Trust
Opiate Dependence, Osteoporosis
Bone Density and Serum Testosterone in Male Methadone Maintained Patients
This is a pilot study designed to answer the question " Do men who are receiving methadone maintenance therapy have lower spinal bone densities compared with age-matched controls who are not receiving methadone therapy?" The…
- Conditions
- Opiate Dependence, Osteoporosis, Erectile Dysfunction, Hypogonadism
- Trial name
- NCT00170339
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hennepin Healthcare Research Institute
Osteoporosis, Chronic Kidney Disease
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
The primary objective of the study is to examine the effect of denosumab on lumbar spine bone mineral density (BMD) after one year of treatment in newly transplanted renal allograft recipients.
- Trial name
- POSTOP (NCT01377467)
- Testing
- Denosumab (Prolia)
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Rudolf Wuethrich
Breast Cancer, Prostate Cancer
Pilot Study of Secondary Causes of Osteopenia/Osteoporosis in Adults With Breast and Prostate Cancer
The investigators hypothesis is that secondary causes of bone loss are prevalent in patients with breast and prostate cancer, and those patients with secondary causes of bone loss are at higher risk for treatment related bone…
- Conditions
- Breast Cancer, Prostate Cancer, Osteopenia, Osteoporosis
- Trial name
- NCT01277562
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- City of Hope Medical Center
Female With Osteoporosis and Chronic Kidney Disease
Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease
Aim of this study is to evaluate in a population of old osteoporotic chronic kidney disease females the effect of denosumab: on bone mineral density (femoral T-score) at 24 months on bone mineral density evolution (femoral…
- Trial name
- HDENO (NCT02792413)
- Testing
- Denosumab
- Where
- 9 sites in France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Montpellier
Hemodyalysis, Kidney Tansplant
Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients
This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general…
- Conditions
- Hemodyalysis, Kidney Tansplant, Osteoporosis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- NCT07141043
- Where
- Romania
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
Osteoporosis, Renal Osteodystrophy
The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients
This is a Phase 2 Multi-Center Clinical Trial (safety and effectiveness trial) in 60 patients (40 denosumab; 20 placebo) who have had a kidney transplant for 12-months or longer with more than 30% of kidney function.
- Conditions
- Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
- Trial name
- ProliaKTx (NCT03960554)
- Testing
- Denosumab Inj 60 mg/ml
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Thomas Nickolas, MD MS
Low Bone Mass, Low Bone Mineral Density
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
The purpose of this study is to assess how effective and safe denosumab is in a population of males with low bone mass at risk of fracture.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis, Osteopenia
- Trial name
- NCT00980174
- Testing
- 60 mg denosumab
- Volunteers
- 242 people
- Sponsor
- Amgen
Osteoporosis, Osteoporosis, Age-Related
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
A 12-month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
- Conditions
- Osteoporosis, Osteoporosis, Age-Related, Osteoporosis Localized to Spine, Age Related Osteoporosis
- Trial name
- NCT03512262
- Testing
- Abaloparatide
- Where
- 34 sites in United States, Italy and 1 more
- Volunteers
- 228 people
- Sponsor
- Radius Health, Inc.
Male Osteoporosis
Novel Combination Therapy for Osteoporosis in Men
Osteoporotic fractures are a key health problem in older men. Although there are drugs approved to treat osteoporosis in men [bisphosphonates, denosumab, and teriparatide (TPTD) or PTH(1-34)], there is a lack of knowledge on how…
- Trial name
- Osteo-Men (NCT03994172)
- Testing
- Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, Calcium citrate tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer, Osteoporosis
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Androgen deprivation therapy (ADT) treatment for prostate cancer decreases the natural hormone called testosterone. This type of therapy is very effective for the treatment of prostate cancer.
- Conditions
- Prostate Cancer, Osteoporosis, Fractures
- Trial name
- NCT00129142
- Testing
- Toremifene Citrate
- Where
- 155 sites in United States, Mexico
- Volunteers
- 1,200 people
- Sponsor
- GTx
Osteoporosis, Prostate Cancer
Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer
RATIONALE: Measuring bone mineral density may help doctors predict whether prostate cancer will come back. It may also help the study of prostate cancer in the future.
- Trial name
- NCT00176579
- Testing
- dual x-ray absorptiometry
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Medicine and Dentistry of New Jersey